Teratogenicity of arotinoids (retinoids) in vivo and in vitro
- 36 Downloads
The effect of structural modifications on the arotinoid molecule, a new class of retinoids, on their teratogenicity in mice was studied. Animals were treated on days 8 and 9 of gestation, the most susceptible stages to retinoid-induced malformations in rodents. The teratogenic potency of the 13 arotinoids tested varied over a dose range of more than five orders of magnitude. Next, we tested whether the quantitative differences in the teratogenicity of these arotinoids correlates with their activity in high density (micromass) cultures of rat embryonic limb bud and midbrain cells. There was a good quantitative correlation between the in vivo teratogenicity and the in vitro activity in limb bud cells but no correlation was found in midbrain cells. Thus, the limb bud cell culture system may be useful for a preliminary testing to select non-teratogenic retinoids. For the risk assessment in humans, however, the in vitro results should be verified in animals studies.
Key wordsTeratogenicity in vivo Teratogenicity in vitro Retinoids Arotinoids Micromass culture
Unable to display preview. Download preview PDF.
- Creech Kraft J, Löfberg B, Chahoud I, Bochert G, Nau H (1989) Teratogenicity and placental transfer of all-trans-, 13-cis-, 4-oxo-all-trans-, and 4-oxo-13-cis-retinoic acid after administration of a low oral dose during organogenesis in mice. Toxicol Appl Pharmacol 100: 162–176CrossRefPubMedGoogle Scholar
- Flint OP (1987) An in vitro test for teratogens using cultures of rat embryo cells. In: Atterwill CK, Steele CE (eds) In vitro methods in toxicology. Cambridge University Press, Cambridge pp 339–363Google Scholar
- Guntakatta M, Matthews EJ, Rundell JO (1984) Development of a mouse embryo limb bud cell culture system for the estimation of chemical teratogenic potential. Teratogen Carcinogen Mutagen 4: 349–364Google Scholar
- Hassell JR, Horigan EA (1982) Chondrogenesis: a model developmental system for measuring teratogenic potential of compounds. Teratogen Carcinogen Mutagen 2: 325–331Google Scholar
- Kamm JJ, Ashenfelter KO, Ehmann CW (1984) Preclinical and clinical toxicology of selected retinoids. In: Sporn MB, Roberts AB, Goodman DS (eds) The retinoids, vol. 2. Academic Press, New York, pp 287–326Google Scholar
- Kistler A (1985) Inhibition of chondrogenesis by retinoids. Limb bud cell cultures as a test system to measure the teratogenic potential of compounds? In: Homburger F. Goldberg AM (eds) In vitro embryotoxicity and teratogenicity tests. Concepts Toxicol, vol 3. Karger, Basel, pp 86–100Google Scholar
- Kistler A, Howard WB (1990) Testing of retinoids for teratogenicity in vivo. In: Packer L (ed) Retinoids. Methods in enzymology (in press)Google Scholar
- Loeliger P, Bollag W, Mayer H (1980) Arotinoids, a new class of highly active retinoids. Eur J Med Chem 15: 9–15Google Scholar
- Renault JY, Malcion C, Cordier A (1989) Limb bud cell culture for in vitro teratogen screening: validation of an improved assessment method using 51 compounds. Teratogen Carcinogen Mutagen 9: 83–96Google Scholar
- Tsuchiya T, Sekita S, Koyama K, Natori S, Takahashi A (1987) Effect of chaetochromin A, chaetochromin D and ustilaginoidin A, bis (naphtho-γ-pyrone) derivatives, on the mouse embryo limb bud and midbrain cells in culture. Cong Anom 27: 245–250Google Scholar